Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT-ALS: Tirasemtiv in ALS
NCT01709149Phase 2Completed
- Sponsor
- Cytokinetics
- Start
- Oct 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of tirasemtiv in amyotrophic lateral sclerosis (ALS), sponsored by Cytokinetics. Started Oct 2012; status: completed.
02
Drugs
tirasemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01709149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709149.